Form 4: Lyra Therapeutics CFO Jason Cavalier Reports Acquisition and Disposal of Common Stock

Jason Cavalier, CFO of Lyra Therapeutics, reports acquiring 420,000 shares of common stock and disposing of 520,000 shares.

Summary

• On January 8, 2025, Jason Cavalier, the Chief Financial Officer of Lyra Therapeutics, reported a transaction involving the company's common stock.
• Cavalier acquired 420,000 shares of common stock.
• Simultaneously, Cavalier disposed of 520,000 shares of common stock.
• Following these transactions, Cavalier directly owns 520,000 shares of Lyra Therapeutics.
• The acquisition involved an award of restricted stock units (RSUs), each representing a contingent right to receive one share of Lyra's common stock.
• The RSUs will vest in three substantially equal installments on July 1, 2025, January 1, 2026, and July 1, 2026, contingent upon continued service to Lyra Therapeutics.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing represents a standard transaction report. The acquisition of RSUs is a positive sign, but the disposal of shares could raise concerns, resulting in a balanced outlook.

Positives

• The grant of RSUs to the CFO aligns his interests with the long-term success of the company.
• The vesting schedule encourages continued service and commitment from the CFO.

Negatives

• The disposal of 520,000 shares by the CFO could be perceived negatively by investors, although the acquisition of RSUs may offset this concern.

Risks

• The value of the RSUs is contingent upon the future performance of Lyra Therapeutics' stock.
• If Cavalier leaves the company before the vesting dates, the unvested RSUs will be forfeited.

Future Outlook

The CFO's future ownership will be influenced by the vesting of RSUs, contingent on continued service.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor management's alignment with shareholder interests.

Stakeholder Impact

• Shareholders may scrutinize the CFO's transactions to assess confidence in the company's prospects.
• Employees may view the RSU grant as a positive sign of management's commitment.

Key Dates

Keywords

Lyra Therapeutics, Jason Cavalier, CFO, Form 4, Common Stock, Restricted Stock Units, RSUs, Beneficial Ownership, Securities, Vesting